MediciNova, Inc. Share Price & Technical Analysis
MNOV · $1.40 (+2.19%)
Healthcare / Biotechnology
$1.40
+2.19%
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
0% return in May, 2% avg return in past 3 year May month.
7% return in 2026, -10% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 31% | -17% | -7% | 0% | 0% | – | – | – | – | – | – | – | 7% |
| 25 | -5% | -20% | -6% | 0% | -7% | -7% | 0% | -13% | 0% | 31% | -6% | -13% | -47% |
| 24 | -7% | 0% | 7% | -13% | 8% | 0% | -13% | 15% | 40% | -19% | 24% | -5% | 37% |
| 23 | 14% | -8% | 0% | -5% | 5% | 10% | 4% | 4% | -12% | -10% | -5% | -17% | -20% |
| 22 | -11% | -4% | 13% | 0% | -11% | 4% | -8% | -9% | 5% | -5% | 24% | -26% | -28% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$68.91M
P/E ratio
—
52W high
$1.96
52W low
$1.17
Volume
12,791
Beta
0.63
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is MediciNova, Inc. share price today?
- MediciNova, Inc. (MNOV) last traded around $1.40 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MNOV have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MNOV. Download the app for real-time alerts.
- How can I analyze MediciNova, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.